Untranslated

86-21-64556180

cpd-service@caerulumpharma.com

Home
About Us
Products
Solutions
FAQs
Contact Us

Home
Products
Intermediates

Products Categories

Antineoplastic
- ACC
- Adenosine A2A
- ALK
- Androgen receptor inhibitor
- Apoptosis stimulant
- ATR
- AXL
- BCl2-BH4
- Bcr-Abl
- BRAF
- BTK
- CDK
- Chk1
- CYP17
- DNA alkylating agent
- EED
- EGFR
- EP4
- ER
- FAK
- FGFR
- FLT3
- Glutaminase
- IDO
- IRA
- KIT
- LXR
- MDM2
- MEK
- MET
- Nrf2
- P90RSK
- P97
- PAKS
- PARP
- PI3K
- Plk-1
- SMYD2
- SRC
- TOPK
- VEGFR
Hypoglycemic drugs
- DPP-4
- SGLT-1
- SGLT-2
Others
- 5HT
- AMPK
- Arginase
- CRF-1
- CXCR2
- FLAP
- FXR
- GABA
- Gi activator
- GR
- JAK
- LABA
- mAChRs
- NF-κB
- NRTI
- PPAR
- RIP1
- S1PR
- SGC
- SYK
- α2δ-1
- αIIbβ3
- β2-adrenoceptor
- σ1

Intermediates

TAK-071
R-268712
CPD1816
CPDD2042
CPDD2040
CPDD2038
CPDD2037
CPDD2036
CPDD2032
CPDD2029
CPDD2035
CPDD2034
CPDD2033
CPDD1800
CPD2031
CPDD0273
CPDD1850
CPDD1848
CPDD0276
CPDD1020
CPDD1847
CAS: 1394003-86-1,IPI-549 Intermediate 1
CPDD1845
CPDD2013
CPDD1040
CPDD1035
CAS:1708974-56-4,FGF401 Intermediate A9
CPDD1843
CAS:Free1217651-75-6,MSC2530818 Intermediate
CPDD1840

<< < Previous 3 4 5 6 7 8 Next > >> Page 7 / 8

Contact Us

3rd Floor, Building 4, 3918 Daye Road, Fengxian District, Shanghai
86-21-64556180
Within China:
sales-cpd@caerulumpharma.com
International:
cpd-service@caerulumpharma.com

Inquiry

For inquiries about our products, please leave your email with us and we will be in touch within 24 hours.Inquiry

Latest News

AstraZeneca receives regulatory boost for oncology drugs

AstraZeneca receives regulatory boost for...

AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

Top 7 Trends In Pharmaceutical Research In 2018

Top 7 Trends In Pharmaceutical Research I...

Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...

ARS-1620: A promising new inhibitor for KRAS-mutant cancers

ARS-1620: A promising new inhibitor for K...

According to a study published in Cell, researchers have developed a specific inhibitor for KRASG12C called ARS-1602 that induced tumor regression in mice. “This study provides in vivo evidence that mutant KRAS can be...

AstraZeneca receives regulatory boost for oncology drugs

AstraZeneca receives regulatory boost for...

AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

Top 7 Trends In Pharmaceutical Research In 2018

Top 7 Trends In Pharmaceutical Research I...

Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...

prev

next

© Copyright - 2010-2022 : All Rights Reserved.

FAQs
Downloadable
Contact Us

QR Code

WhatsApp Online Chat !

TOP

Previous Maximize